Boston Scientific (BSX) Reports In-Line Q3 EPS, Offers Q4 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
- Array Technologies and Shoals Technologies agree to stock-for-stock merger
- AMD gets bullish pre-earnings call from Lynx as server CPU demand accelerates
- Marathon Petroleum to sell two refineries to CVR Energy for $4.2B
- AMD forecast eases AI spending fears as data-center sales surge
- Moderna shares rise ahead of Thursday earnings report
- After-Hours Movers: AMD, SMCI, SWKS, NRIX, TOST, BKNG
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
Boston Scientific Announces Results For Third Quarter 2017
October 26, 2017 6:30 AM EDTMARLBOROUGH, Mass., Oct. 26, 2017 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated sales of $2.222 billion during the third quarter ended September 30, 2017. This represents growth of 5.6 percent on a reported basis and 5.7 percent on an operational basis (excludes the impact of changes in foreign currency exchange rates), all compared to the prior year period. The company reported GAAP earnings of $283 million or $0.20 per share (EPS), compared to GAAP earnings of $228 million or $0.17 a year ago, and achieved adjusted earnings per share of $0.31 for the period, compared to $0.27 a year ago.
... More


